Sencell16
Lifecare’s Sencell sensor is an implantable micro-sensor for subcutaneous location, long time, continuous, wireless, real time monitoring of interstitial glucose for diabetes management.
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Sencell16 project word cloud
Explore the words cloud of the Sencell16 project. It provides you a very rough idea of what is the project "Sencell16" about.
Project "Sencell16" data sheet
The following table provides information about the project.
| Coordinator |
LIFECARE AS
Organization address contact info |
| Coordinator Country | Norway [NO] |
| Project website | http://www.lifecare.no |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2016-2017 |
| Funding Scheme | SME-1 |
| Starting year | 2016 |
| Duration (year-month-day) | from 2016-08-01 to 2016-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | LIFECARE AS | NO (BERGEN) | coordinator | 50˙000.00 |
Map
Project objective
The SENCELL Glucose Monitoring System includes an osmotic pressure sensor, transmitter and mobile medical application. The miniaturized sensor is designed to be implanted into the subcutaneous space of arm wrist or other suitable body sites and requires no battery or wires for the sensor operation and for communication with the transmitter. After insertion, the sensor is designed to function noninvasively, automatically, and continuously for a long term duration that is comparable or longer than existing product alternatives.
The miniaturized SENCELL is designed to continuously measure glucose in the interstitial fluid for a long term duration that is comparable or longer than existing product alternatives. Unlike currently used glucose sensors, the Sencell is intended to be implanted subcutaneously on the arm wrist or other subcutaneous places in the body with no sensor part protruding from the skin.
Encased in a biocompatible material, the device utilizes a unique osmotic pressure assessment technology, which translates the signal of a physical miniaturized osmotic pressure cell into an accurate glucose reading that can be used for determination of insulin doses and to generate warning signals in case of hypoglycemia or hyperglycemia development.
The inner core of the device is the unique and proprietary osmotic patented pressure cell, which is covered on one side by a semi-permeable membrane. The membrane is enclosed inside the top of a cavity where the pressure transducer is also located. The cavity contains Concanavalin A and Dextran.
The use of ConA/Dextran as enzymatic component significantly improves the sensitivity to changes in the blood sugar level while reducing the influence from other substances in the blood. In the final product, the measurement is then relayed to the transmitter. The entire measurement is designed to be done autonomously and independently without any prompting by the user. However, the user can induce a measurement at any time
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SENCELL16" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SENCELL16" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.1.3.)
DIAdIC (2019)
Evaluation of Dyadic Psychoeducational Interventions for People with Advanced Cancer and their Informal Caregivers (DIAdIC): An international randomized controlled trial
Read More